TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.
Metrics to compare | 6549 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6549PeersSector | |
---|---|---|---|---|
P/E Ratio | −25.6x | −17.3x | −0.5x | |
PEG Ratio | −1.87 | 0.02 | 0.00 | |
Price/Book | 7.9x | 2.9x | 2.6x | |
Price / LTM Sales | - | 28.1x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 42.9% | |
Fair Value Upside | Unlock | −11.2% | 6.2% | Unlock |